Abstracts tagged "Mouse Models, Other"

Abstract Number: 1739 • ACR Convergence 2025
Acute Transcriptomic Response of Synovium and Dorsal Root Ganglia to Joint Injury
Michael Newton¹, Lai Wang², Anne-Marie Malfait³, Rachel Miller² and Tristan Maerz⁴, ¹University of Michigan, South Lyon, MI, ²Rush University Medical Center, Chicago, IL, ³Rush University, Oak Park, IL, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: In arthritic synovium, emerging clinical evidence suggests crosstalk between synovial cells and dorsal root ganglion (DRG) neurons drives nerve sprouting and pain sensitization [Bai+…
Abstract Number: 0983 • ACR Convergence 2025
Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Grace Frechette, Thamotharampillai Dileepan, Marc Jenkins and Shawn Mahmud, University of Minnesota, Minneapolis
Background/Purpose: Mixed connective tissue disease (MCTD) is a systemic autoimmune disorder marked by a U1-small nuclear ribonucleoprotein (U1-snRNP) autoantibody. The majority of U1-snRNP antibodies in…
Abstract Number: 0965 • ACR Convergence 2025
Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
Kamal Saba¹, Rong Huang², Priyanka Verma¹, M Asif Amin¹ and John Varga¹, ¹University of Michigan, Ann Arbor, MI, ²Purdue University, West Lafayette, IN
Background/Purpose: Systemic sclerosis (SSc) is characterized by progressive fibrosis driven by sustained fibroblast activation and senescence. Nicotinamide N-methyltransferase (NNMT), a SAM-dependent enzyme, is upregulated in…
Abstract Number: 0922 • ACR Convergence 2025
Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Sex Correlates
Juan Liang¹ and kaiyuan zi², ¹Gempharmatech, Nanjing, Jiangsu, China, ²Gempharmatech, Nanjing, Jiangsu, Jiangsu, China
Background/Purpose: Complement component C3 plays a central role in the alternative pathway (AP) and is implicated in the pathogenesis of C3 glomerulopathy (C3G), a rare…
Abstract Number: 0915 • ACR Convergence 2025
A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models
Yuhao Qin¹, Huan Wang¹, Han Gao¹, Chongqi Zhang¹, Chengpan Wang¹, yanru fan¹, wei ye¹, yuan lin¹, Lu Su², Wenming Ren¹ and cheng liao¹, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China (People's Republic), ²Jiangsu Hengrui Pharmaceuticals, Shanghai, Shanghai, China
Background/Purpose: Pathological elevation of type I interferon (IFN-I) , B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) has been robustly documented across multiple autoimmune…
Abstract Number: 0903 • ACR Convergence 2025
Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling
Catherine Wioland¹, Corinne Vedrine², Caroline Walter¹, Fanny Marque², Thomas Dannequin², Melanie Cecci¹, David Buffet¹, Cindy Schmid¹, Elena Degl'Innocenti¹, Gautier Robert¹, Grazyna Wieczorek¹, David Schubert¹, Catriona Paape¹ and Isabelle Isnardi³, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ³Novartis, Gueberschwihr, France
Background/Purpose: B cells are key players in the pathogenesis of Sjögren’s disease (SjD) and other systemic auto-immune diseases, supporting B cell depletion as an attractive…
Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Xueting Yuan¹, Menghua Cai², Lu Gao², Chen Yu³, Jia Shi⁴, Yinghui Li², jiuliang Zhao¹, Dong Xu⁵, Chaojun Hu¹, Mengtao Li⁶, Xiaofeng Zeng⁷, jianmin Zhang² and Qian Wang⁶, ¹Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ²Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), ³Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁴University of Washington, Seattle, WA, ⁵Peking Union Medical College Hospital, Dong Cheng District, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…
Abstract Number: 0113 • ACR Convergence 2025
ZEB2 and MLCK1 may impair gut barrier integrity in MIF-Deficient SKG Mice
Shaghayegh Foroozan Boroojeni¹, Mansi Aparnathi², Akihiro Nakamura³, Zoya Qaiyum² and Nigil Haroon⁴, ¹University Health Network/University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³Queen's University, Kingston, ON, Canada, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory condition that primarily affects the musculoskeletal system and has multifactorial origins. The majority of AxSpA patients experience…
Abstract Number: 0110 • ACR Convergence 2025
SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses
Yuka Nakao¹, Astha Patel¹, Bahram Razani², Steven yu¹, Steven Lazarevsky², Marlys Fassett² and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²UCSF Department of Dermatology, San Francisco, CA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are chronic immune-mediated diseases affecting millions, yet early immunologic triggers remain poorly defined. Therapies targeting TNFα, IL-17, and…
Abstract Number: 2579 • ACR Convergence 2025
Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease
Richard Moore¹, Lihong Huo¹, Colin Koziel¹, Barry Stripp², Tiphanie Vogel³, Daniel Wallace⁴ and Caroline Jefferies⁵, ¹Cedars-Sinai, Beverly Hills, CA, ²Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ³Baylor College of Medicine, Houston, TX, ⁴Cedars Sinai Medical Center, Studio City, CA, ⁵Cedars-Sinai Medical Center, Beverly Hills, CA
Background/Purpose: COPA syndrome is an autosomal dominant disease caused by missense mutations within the COPA gene. Typical onset begins during childhood with patients developing lung…
Abstract Number: 0106 • ACR Convergence 2025
Investigation of DNA Methylation Inhibition in a Mouse Model of Ankylosing Spondylitis
Goh Murayama¹, Kurisu Tada², Naoto Tamura³, Eri Hayashi¹, Taiga Kuga⁴, Ken Yamaji⁵ and HOSHIKO FURUSAWA⁶, ¹Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, ³Juntendo University School of Medicine, Tokyo, Japan, ⁴Juntendo University, Tokyo, Japan, ⁵Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, ⁶juntendo, tokyo, Japan
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by enthesitis in axial joints, bone erosion near the entheses, and subsequent irreversible ankylosis due…
Abstract Number: 1857 • ACR Convergence 2025
Role of autoantigen-specific reactivity in the pathogenesis of murine interstitial lung disease model with anti-MDA5 antibody mouse model
Atsubumi Ogawa¹, Ran Nakashima², Tsuneyasu Yoshida³, Keisuke Hirobe¹, Yasuhiro Nohda¹, Tsuneo Sasai¹, Mirei Shirakashi², Ryosuke Hiwa¹, Hideaki Tsuji¹, Shuji Akizuki², Hajime Yoshifuji², Kosaku Murakami⁴, Norimichi Nomura⁵, Atsuyasu Sato⁶, Motomu Hashimoto⁷ and Akio Morinobu⁸, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ³Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁵Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁷Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Sakyo-ku, Japan, ⁸Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Anti-Melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5-DM) is often complicated by rapidly progressive interstitial lung disease (RP-ILD) and has a poor prognosis. Although there has…
Abstract Number: 0098 • ACR Convergence 2025
The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:
Archita Srinath¹, Sungsin Jo², Daniele Mauro³, Mariia Korshko⁴, Mansi Aparnathi⁵, Shaghayegh Foroozan Boroojeni⁶, Tae-Hwan Kim⁷, Francesco Ciccia⁸ and Nigil Haroon⁹, ¹University of Toronto, Toronto, ON, Canada, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³University of Campania, Italy, Naples, Italy, ⁴UHN, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶University Health Network/University of Toronto, Toronto, ON, Canada, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸University of Campania, Naples, Italy, ⁹Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however over 40% of patients…
Abstract Number: 1828 • ACR Convergence 2025
CD14+CXCL10+Monocytes Remodel the Peripheral Immune Network in sJIA via UBE2D1-Driven Inflammatory Programming
Xuemei Tang¹, Qiang Luo², Jun Yang³, Haiguo Yu⁴, Xinglin Wu¹, Xiwen Luo⁵, Xi Yang⁵, Zhiyong Zhang⁵, Yunfei An⁵, Xiaodong Zhao¹ and Hongmei Song⁶, ¹Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), ²Department of Rheumatology and Immunology, Children’s Hospital of Chongqing Medical University, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China (People's Republic), ³Rheumatology and Immunology Department of Shenzhen Children's Hospital, Shenzhen, ⁵¹⁸¹⁰⁰, China., Shenzhen, China (People's Republic), ⁴Department of Rheumatology and Immunology, Nanjing Children's Hospital, Nanjing, ²¹⁰⁰⁰⁰, China., Nanjing, China (People's Republic), ⁵Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), ⁶Pediatric Department of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, ¹⁰⁰⁰⁰⁰, China., Beijing, China (People's Republic)
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disorder characterized by systemic immune dysregulation. However, reliable biomarkers to predict its unpredictable disease course are…
Abstract Number: 1804 • ACR Convergence 2025
Pharmacology of LEVI-04, a novel treatment for OA
Simon Westbrook¹ and Kerry af Forselles², ¹Levicept Ltd, Sandwich, United Kingdom, ²Levicept, Sandwich, United Kingdom
Background/Purpose: LEVI-04 is a novel fusion protein comprising the extracellular domain of p75 neurotrophin receptor (p75NTR) coupled to IgG1 Fc, being developed for the treatment…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].